About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

AIDS Research and Human Retroviruses

Editor-in-Chief: Thomas Hope, PhD

ISSN: 0889-2229 • Published Monthly • Online ISSN: 1931-8405

Current Volume: 30

Latest Impact Factor* is 2.457

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Mary Ann Liebert, Inc. Submission Benefits Package

    Your submission to AIDS Research and Human Retroviruses provides you with robust tools and support to ensure maximum impact and readership for your work. By submitting your manuscript, you’ll receive:

    • Rapid, rigorous peer-review and editorial attention
    • Immediate deposit to PubMed and other indexing services upon online publication
    • Exposure to thousands of thought-leaders in your field, maximizing readers, citations, and downloads
    • Fast Track online-ahead-of-print publication
    • Global availability in over 170 countries
    • Open Access publication options
    • Opportunity to join AuthorCite®
      Exclusively licensed by Mary Ann Liebert, Inc., AuthorCite® delivers a 360-degree view of your article from submission to publication to market impact. With an AuthorCite® membership, you’ll receive end-to-end manuscript submission tracking, a custom online microsite to promote you and your research, a professional suite of metrics and analytics to measure the impact of your article, 30-day OpenLink™ article sharing, and much more.


    Submitting Your Manuscript

    Click here to submit your paper via our fast and user-friendly electronic submission system.


    Manuscript Revisions

    To upload a revision of a paper, the submitting author should log in to their Author Center at http://mc.manuscriptcentral.com/aidsresearch and click on “Revised Manuscripts in Draft.”

    Please be sure to follow the Instructions for Authors below on Manuscript Preparation.  Authors whose submissions do not comply with the Instructions for Authors will have their papers un-submitted so that the file(s) may be adjusted accordingly. Directions regarding the necessary corrective actions will be provided in an email to the corresponding author at the time the paper is un-submitted. The submitting author/agent will then be provided the opportunity to re-upload the corrected file(s). If a paper is un-submitted, the paper will reside in the corresponding author’s “Author Center” as a draft, and the submitting author/agent will be able to make the necessary adjustments.  


    Instructions for Authors

    AIDS Research and Human Retroviruses is a peer-reviewed journal in the English language. The Journal will publish Full and Short Communications, Letters to the Editor, Perspectives, Sequence Notes, Mini-reviews, and Conference or Workshop Summaries as deemed appropriate.

    To help defray the cost of printing, the Publisher requests that page charges of $65 per printed page be paid by all authors who have funds available from research grants or from their institutions. It should be noted that ability to pay page charges is not a prerequisite for publication in the Journal.
     

    Full Communications should be presented in the format described below.

    Short Communications, also subject to peer-review, are intended for the presentation of brief observations that do not warrant a full-length text, but also are not preliminary results. Include an abstract; do not use section headings in the body of the text; report methods, results, and discussion in a single section. Reference citations are identical in style to those of full-length papers, but appropriately abbreviated.

    Images in HIV Research:  Images can tell a research story and capture the imagination as well as provide scientific information about spatial relationships and context.   We welcome submissions that contain striking images that illustrate and illuminate a research story, make a timely and relevant point, emphasize a new and emerging concept, or are stunning and beautiful.

    Submission Requirements:

    • Text should be no more than 500 words
    • Limit of four references
    • Images must be uploaded at a minimum of 300 DPI. 
    • Images must be in either .TIFF or .EPS files.  .JPEG files cannot be used as the resolution of these files is too low.

    Images may be considered for use on the Journal cover in the issue the submission is published.

    All submissions are subject to peer review.  All accepted submissions will be deposited to Medline after final publication.

    Letters to the Editor can be on any issue relevant to the field of human retroviruses. They must be brief (one or two journal pages) and appropriately documented by data. Letters can be sent to the Editor-in-Chief or to the basic science or clinical Editors, and may be subject to review.

    Mini-reviews and Perspectives may be solicited by the Editors or submitted independently. Mini-reviews are brief summaries of new developments in the field of human retroviruses. Perspectives are more representative of an opinion about an area of the field or a direction of research. The length for either should not exceed seven journal pages, and both may be subject to peer-review.

    Sequence Notes offer more rapid publication of papers that present novel sequence data in a brief format. They are generally no more than 3 or 4 journal pages.  Include an abstract of not more than 150 words, but do not use section headings in the text, and limit the references to 15.  Sequence Notes, like all papers, should be uploaded here.
    Allow 2-3 weeks for the initial evaluation.

    Senior Clinical Editor
    Carlos del Rio, Professor of Medicine (Infectious Diseases), Emory Center for AIDS Research, Atlanta, Georgia

    Editors - Basic Sciences

    Cell Biology
    Birgitta Åsjö, Centre for Research in Virology, University of Bergen, Bergen, Norway

    Pathogenesis
    Mario Stevenson, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA

    Vaccines
    Michael Betts, University of Pennsylvania, Philadelphia, PA

    Animal Models
    Ronald C. Desrosiers, New England Regional Primate Research Center,
    Southborough, MA

    Molecular Biology/Other Human Retroviruses
    Patrick Green, The Ohio State University, Columbus, OH

    Sequence Notes
    Brian Foley, HIV Sequence Database, Los Alamos National Laboratory, Los Alamos, NM

    Editors - Clinical Investigations

    Complications of Therapy
    Mariana Gerschenson, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI

    Epidemiology
    Mauro Schechter, Professor of Infectious Diseases, Head, AIDS Research Laboratory, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil            

    Editor-in-Chief
    Thomas Hope, Ph.D., Feinberg School of Medicine, Northwestern University,  Chicago, IL

     

     

    Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal. 

    Upon acceptance of any manuscript, all authors will receive a follow-up email with instructions on how to complete our online Copyright Agreement form.  It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications.

    FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM MAY RESULT IN A DELAY OF PUBLICATION.

    The corresponding author is responsible for communicating with coauthors to make sure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.

    Preparation of Manuscript


    Follow all submission guidelines to avoid delays in processing and publication. Type manuscripts double-spaced. Leave ample margins on the sides, top, and bottom of the page. Manuscripts should be submitted in Microsoft Word.

    The title page should include the authors’ names and affiliations, and a running title of about 45 characters, including spaces. Please indicate contact information for the corresponding author, including a mailing and/or street address, telephone and fax numbers, and e-mail address. The second page must consist of an abstract of not more than 250 words, which should be self-explanatory without reference to the text. Full communications are structured using the following headings: abstract, introduction, materials and methods, results, discussion, acknowledgments, sequence data, and references. Number pages consecutively. At the end of the manuscript, give the name and address of the individual to whom reprint requests should be directed. The inclusion of that person’s e-mail address is also strongly encouraged.

    The authors may suggest suitable referees in a cover letter, but must provide accurate contact information for all such individuals, including fax numbers. Please follow the requested style to avoid delays in publication.

    INSTANT ONLINE PUBLICATION

    The Journal publishes all accepted papers within 72 hours of acceptance in their unedited, uncorrected format.  It is important to note that the information that is published online, and in all indexing services, is pulled directly from the data that is populated into the fields in Manuscript Central – NOT from the manuscript file – when the paper is originally uploaded to the system for peer review.  Consequently, any errors contained in the system will remain on our website and all indexing services, including Medline, until the next revision of the article is published.  As such, it is critical that authors enter all authors’ names correctly into the system at the time of submission.

    The next revision will take place after the corresponding author sees page proofs, makes any necessary corrections, and returns the changes to the Publisher.  Once the alterations are completed, the revised version will be published on our website, and the newly corrected information will then be released to Medline/PubMed, in addition to any other indexing services in which the Journal is included.

    Please note that the typical time between acceptance of a paper and page proof distribution is approximately 4-8 weeks depending on the length and complexity of the paper.

    Nomenclature


    AIDS Research and Human Retroviruses has adopted the recommendations of the Executive Committee of the International Committee on Taxonomy of Viruses (ICTV) (Ref: Science 232:1486, 1986, and Nature 321:644, 1986) to designate viruses associated with AIDS. The Committee’s suggestion was to use HIV (human immunodeficiency virus) or the generic name for this class of human retroviruses. The Committee also recommended maintaining the specific strain names (LAV-1BRU, LAV-1LOI,  HTLV-IIIB,  HTLV-IIIRF,  ARV1 . . .) in the interest of continuity and appreciation for the biologic and molecular differences of the individual strains. Thus, for the sake of accuracy, the editors encourage the use of specific strain names in experimental details.

    Sequence Data


    AIDS Research and Human Retroviruses requires submission of accession numbers with any manuscript that uses sequence data. The numbers must be listed in a separate section following acknowledgments. Accession numbers can be obtained from Genbank, EMBL, or DDBJ. See http://www.ncbi.nlm.nih.gov/genbank/index.html for information, or send e-mail to info@ncbi.nlm.nih.gov

    Tables


    Submit each table with its title in a separate file. Use Arabic numerals to number tables. Each table must stand alone, i.e., contain all necessary information in the caption, and the table itself must be understood independently of the text. Details of experimental conditions should be included in the table footnotes. Table legends and footnotes should be double-spaced. Information that appears in the text should not be repeated in tables, and tables should not contain data that can be given in the text in one or two sentences.

    Illustrations



    Figures/images should be presented according to these guidelines:

    • Do not include any illustrations as part of your text file.
    • Do not prepare any figures in Word as they are not workable.
    • Line illustrations must be submitted at 1200 DPI.
    • Halftones and color photos should be submitted at 300 DPI.
    • Please submit either .TIFF or .EPS files.
    • Color art must be saved as CYMK not RGB or INDEX. If RGB files are submitted, the files will be converted to CYMK, and some slight color variation may occur.
    • Do NOT submit PowerPoint or Excel files.


    Color Artwork

    The Journal will publish color illustrations, but the author must subsidize the cost of the color printing. For further details, contact the Publisher.

    Acknowledgments

    Collaborations, sources of research funds, and other acknowledgments should be listed in a separate section at the end of the text ahead of the References section.
     

    AUTHOR DISCLOSURE

    All authors are expected to disclose any institutional or commercial affiliations that might pose a conflict of interest regarding the publication of a manuscript. Institutional affiliations, as indicated on the title page, should include all corporate affiliations and any funding sources that support the work. Other types of affiliation, including consultantships, honoraria, stock ownership, equity interests, arrangements regarding patents, or other vested interests should be disclosed in the Acknowledgments section.

     

    References

    All references must be cited in the text. Cite references within the text by a superscript Arabic number. Number references in the order that they appear in the text. Double-space the references and triple-space between each listing. When there are more than six authors, it is acceptable to list the first three followed by “et al.” Use the appropriate styles:

    Journals
    (1) surname of author(s), initials, (2) paper title, (3) journal, (4) year of publication, (5) volume number, and (6) first and last page of citation. Example: Williams N: T cells on the mucosal frontline. Science 1998;280:198–200.

    Books
    (1) surname of author(s), initials, (2) chapter title, (3) title of book, (4) editors of book (if applicable), (5) edition of book (if applicable), (6) publisher, (7) city of publication, (8) year of publication, and (9) first and last page reference. Example: Bolognesi D: HIV vaccines. In: Immunology of HIV infection. (Gupta S, ed.) Plenum Medical, New York, 1996, pp. 561–576.

    Patents
    (1) country of original registration, (2) patent number, (3) month, day, and year of issuance.

    When data from an unpublished source are presented, supply complete information, e.g., researcher’s name and location. If work is in press, give the journal in which it is to be published or the publisher.

    Permissions

    The author must obtain permission to reproduce figures, tables, and text from previously published material. Written permission must be obtained from the original copyright holder (generally the publisher, not the author or editor) of the journal or book concerned. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be included in the reference list. Written permission must be obtained from the author of any unpublished material cited from other laboratories, and should accompany the manuscript. All permissions listings must be shown in manuscript—they cannot be entered on proofs.

    Reprints

    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    Publisher

    The Journal is published monthly by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, New Rochelle, NY 10801-5215.  Telephone: (914) 740–2100; fax: (914) 740–2101. 

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Viral Immunology

    Viral Immunology

    The only journal reporting on all aspects of the rapidly growing field of viral immunology, with comprehensive coverage of immune responses to viral infections from basic mechanisms to clinical applications.

    Journal of Interferon
    & Cytokine Research

    Journal of Interferon
    & Cytokine Research

    Presents the latest findings and reviews of research covering IFNs and cytokines, their relevance to chronic and acute disease, studies involving cytokine biology, mechanisms of IFN action, and their role in virus infection.

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

    AIDS Patient Care and STDs

    AIDS Patient Care and STDs

    Provides current advances in this rapidly evolving field with the latest research and reports in diagnostics and therapeutics designed to prolong the lifespan of patients with HIV/AIDS and improve their quality of life.

Browse All Publications »